ENO1 and breast cancer: We used inhibitors to target the most commonly aberrantly activated pathways and found that inhibition of ERK1/2 signaling with SCH772984 suppressed ENO1 protein expression in BC cells in a 24-h period (Fig. 4C and Supplementary Fig. 2A).